跳至主要内容
临床试验/NCT00823004
NCT00823004已完成1 期

GnRH Antagonist /Letrozole Versus Microdose GnRH Agonist Flare Protocol in Poor Responders Undergoing in Vitro Fertilization

Yazd Research & Clinical Center for Infertility1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2008年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
120
试验地点
1
主要终点
pregnancy rate

研究概览

简要总结

Failure to respond to controlled ovarian hyperstimulation (COH) is still a major concern in assisted reproduction and there is no consensus on the ovarian stimulation choice regime for poor responders.

Aim: To evaluate and compare the efficacy of a microdose GnRH agonist flare (MF) and a GnRH antagonist/letrozole (A/L) protocols in poor responders undergoing in vitro fertilization (IVF).

Methods: One hundred eighty poor responder patients will be randomized to an ovarian stimulation protocol with either a MF or a letrozole and high dose FSH/hMG and flexible GnRH antagonist protocol.

详细描述

All women receive 21 days of an oral contraceptive. A MF protocol will be used for ovarian stimulation in 90 patients. Three days after the last pill, a GnRH-agonist buserelin (Suprefact, Aventis Pharma, Frankfurt, Germany) 50 µg SC twice daily will be initiated and two days after that, recombinant FSH (Gonal-F, Serono, Aubonne, Switzerland) or hMG (Merional, IBSA, Lugano, Switzerland) 300-450 IU/day will be administered. Ninetyty patients will be assigned to an A/L protocol. After oral contraceptive withdrawal bleeding on day 3 of cycle, recombinant FSH or hMG 300-450 IU/day will be initiated and letrozole (Femara, Novartis, East Hanover, NJ) 5 mg/day will be administered for 5 days. When the dominant follicle reached 14 mm in mean diameter, ganirelix acetate (Antagon, Organon, West Orange, NJ) 0.25 mg SC daily will be started.

Patients weill be monitored by serial vaginal ultrasonography and measurement of serum E2 level. When at least two follicles with a mean diameter of 18 mm will be achieved hCG (Pregnyl, Organon, Oss, the Netherlands) 10000 IU will be administered. Cycle cancellation will be considered when fewer than two follicles with normal growth pattern weill be noted.

Oocyte retrieval will be performed 34-36 hours after hCG administration. Conventional IVF or intracytoplasmic sperm injection (ICSI) will be performed as appropriate. Embryos with 4-6 equally sized blastomers on day 2 with ≤ 20% fragmentation and no multinucleation will be considered top quality embryos. Embryos with 2-6 equally or unequally blastomers with ≤20% fragmentation and no multinucleation will be considered good quality embryos. Embryos will be transferred on day 2 or 3 under ultrasound guidance, with a C.C.D. embryo transfer catheter ( Laboratoire C.C.D., Paris, France). Luteal support with progesterone in oil (Progesterone, Aburaihan Co., Tehran, Iran) 100 mg daily IM will be started on the day of oocyte retrieval.

Serum β-hCG level will be measured 14 days after embryo transfer and a transvaginal ultrasonography will be performed 3 weeks after positive β-hCG for documentation of gestational sac and fetal heart activity. Clinical pregnancy will be considered as the presence of a gestational sac with fetal heart activity.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

性别
Female
接受健康志愿者

入选标准

  • at least one previous failed IVF cycle in which three or fewer follicles with a mean diameter of 16 mm were achieved, and/or
  • serum E2 level measured on the day of hCG administration was ≤500 pg/ml

排除标准

  • day 3 serum FSH level ≥12 mIU/mL
  • there is no age limit

研究组 & 干预措施

1

Active Comparator

A/L: Poor responders who will receive letrozole and GnRH antagonist for ovarian stimulation

干预措施: letrozole (Drug)

1

Active Comparator

A/L: Poor responders who will receive letrozole and GnRH antagonist for ovarian stimulation

干预措施: oral contraceptive (Marvelone) (Drug)

1

Active Comparator

A/L: Poor responders who will receive letrozole and GnRH antagonist for ovarian stimulation

干预措施: recombinant FSH or hMG (Drug)

1

Active Comparator

A/L: Poor responders who will receive letrozole and GnRH antagonist for ovarian stimulation

干预措施: ganirelix acetate (Drug)

2

Active Comparator

MF: In this arm poor responders are treated by microdose GnRH agonist flare protocol

干预措施: oral contraceptive (Marvelone) (Drug)

2

Active Comparator

MF: In this arm poor responders are treated by microdose GnRH agonist flare protocol

干预措施: GnRH agonist (buserelin) (Drug)

2

Active Comparator

MF: In this arm poor responders are treated by microdose GnRH agonist flare protocol

干预措施: recombinant FSH or hMG (Drug)

结局指标

主要结局

pregnancy rate

时间窗: 5 weeks

次要结局

  • stimulation outcomes(2 weeks)

研究者

发起方
Yazd Research & Clinical Center for Infertility
申办方类型
Other
责任方
Principal Investigator
主要研究者

homa oskouian

fellowship

Yazd Research & Clinical Center for Infertility

研究点 (1)

Loading locations...

相似试验